Synta Pharmaceuticals Corporation

Servier Pharmaceuticals LLC

Agios Pharmaceuticals, Inc.

Les Laboratoires Servier

Shijie Zhang

Weiwen Ying

Dinesh U Chimmanamada

Lijun Sun

David James

Kevin Paul Foley

Zhenjian Du

Junghyun Chae

Teresa Przewloka

Howard P Ng

Zachary Demko

Elena Kostik

Hao Li

Dan Zhou

Shuzhen Qin

Keizo Koya

Chi-Wan Lee

Minghu Song

Stefan M Schweizer

James G Barsoum

Mitsunori Ono

Kevin M Foley

Shoujun Chen

Jun Jiang

Yumiko Wada

Noriaki Tatsuta

Joseph A Burlison

Teresa Kowalczyk-Przewloka

Chong-Hui Gu

Yu Xie

Yaming Wu

Mats Harald Holmqvist

Chih-Yi Yu

Jacob Paul Sizemore

Jerome Mahiou

Yuniko Wada

Wenli Ding

Nha Huu Vo

Teresa Kowalcyzk-Przewloka

K Koya

M Ono

Teresa Kowalczyk-Prezewloka

Stefan Michael Schweizer

The present application relates to a method for preparing a substantially and diastereomerically pure crystalline ethanol solvate of Compound IIa and its use for synthesizing Ivosidenib.

Method for preparing ivosidenib and an intermediate thereof

Provided herein are various salts, including tris(hydroxymethyl)aminomethane salts and sodium salts, as well as various crystalline forms of the compound represented by the structural formula: Also provided are pharmaceutical compositions comprising these salts and crystalline forms, methods for their manufacture, and uses thereof for treating conditions, including but not limited to conditions that would benefit from inhibition of dihydroorotate dehydrogenase (DHODH).

Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.

Ivosidenib forms and pharmaceutical compositions

Provided are compounds useful for treating cancer and methods of making the compounds and intermediates described herein.

Therapeutically active compounds and their methods of use

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound.

Triazole compounds that modulate HSP90 activity

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Triazole compounds that modulate Hsp90 activity

The present invention relates to substituted pyrrole compounds of formula I and compositions comprising substituted tri-substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a tri-substituted' triazole compound of the invention, or a pharmaceutical composition comprising such a compound.

Triazole compounds that modualte HSP90 activity

Triazone compounds that modulate HSP90 activity

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable Ris an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R. Substituent Ris defined herein.

Pyrazole compounds that modulate HSP90 activity

Growing community of inventors

Nashua, NH, United States of America

Shijie Zhang